Skip to content
2020 FDA Approvals: A Year in Review
CDER, Center for Drug Evaluation and Research, FDA, FDA Approvals, Food and Drug Administration, Magellan Health, Magellan RX, Magellan Rx Management, New Drugs, Novel agents, Novel drugs, Orphan Drugs
Alternative Cost-Saving Strategies for Innovative Treatments: Will Medicaid Enter the Value-Based Pricing Market?
Traditional Drug to Biologic: A Change 10 Years in the Making
Biologics, Biosimilars, Drug Approvals, FDA, Magellan, Magellan Health, Magellan Healthcare, Magellan RX, Magellan Rx Management, Traditional Drugs
2019 FDA Approvals: A Year in Review
Biosimilairs, FDA, FDA Approvals, Magellan Health, Magellan RX, Magellan Rx Management, New Drugs, Novel drugs, Orphan Drugs, Trend Alert
Drone-to-Door – The Ascent of The Airborne Pharmacy
“Drug Shortages: Root Causes and Potential Solutions” – Insight from a FDA Task Force
Mental Health in America – Perception and Reality 30 Years Later
21st Century Measles Outbreak
